Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth
muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors …

Background QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination
of the long-acting β 2-agonist indacaterol and long-acting muscarinic antagonist …

Although chronic obstructive pulmonary disease (COPD) is a major global health problem
with a rising incidence and morbidity, few pharmacotherapeutic advances have been made …

Background Indacaterol is an inhaled long‐acting beta 2‐agonist that is administered once
daily and has been investigated as a treatment for chronic obstructive pulmonary disease …

Fixed dose combination (FDC) dual bronchodilators that co‐administer a long acting β2‐
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …

Purpose Dual therapy with bronchodilators of different pharmacological classes may
produce greater lung function improvements than either drug alone. However, the …

Introduction Dual bronchodilator therapy is reserved as a second-line treatment in patients
with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function …

Background Bronchodilators are central to the symptomatic management of patients with
COPD. Previous data have shown that inhaled indacaterol improved numerous clinical …

Objectives To develop a longitudinal statistical model to indirectly estimate the comparative
efficacies of two drugs, using model-based meta-analysis (MBMA). Comparison of two oral …